Business Context and Reporting Period
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing peptide-based therapies. The company reported unaudited results for the three and nine months ended September 30, 2016. It had no approved products and had generated no product revenue.
- PTG-100: Completed a Phase 1 trial and planned to initiate a Phase 2b trial in moderate-to-severe ulcerative colitis by the end of the fourth quarter of 2016.
- PTG-200: In IND-enabling studies, with a Phase 1 trial planned for 2017.
- PTG-300: In preclinical development, with IND-enabling studies planned for 2017.
- The company completed its initial public offering in August 2016 and began trading on Nasdaq.
Financial Performance and Position
| Metric | Three Months Ended September 30, 2016 | Three Months Ended September 30, 2015 | Nine Months Ended September 30, 2016 | Nine Months Ended September 30, 2015 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $5.6 million | $3.2 million | $16.9 million | $7.6 million |
| General and administrative expense | $1.6 million | $0.9 million | $4.4 million | $2.2 million |
| Total operating expenses | $7.1 million | $4.0 million | $21.3 million | $9.8 million |
| Net loss | $7.1 million | $3.4 million | $25.9 million | $9.4 million |
| Net loss attributable to common stockholders | $7.4 million | $3.5 million | $26.5 million | $9.4 million |
| Basic and diluted loss per share | $0.87 | $12.79 | $8.62 | $38.32 |
Loss per share comparisons were significantly affected by the reverse stock split and the increase in shares outstanding following the IPO and preferred-stock conversion.
- Cash and cash equivalents were $96.0 million at September 30, 2016, compared with $4.1 million at December 31, 2015.
- Cash, cash equivalents and available-for-sale securities totaled $98.5 million at September 30, 2016.
- Total assets were $102.8 million; stockholders’ equity was $97.5 million; accumulated deficit was $53.3 million.
- The company had no outstanding debt and no credit facility or committed source of capital.
- Net cash used in operating activities was $20.3 million for the first nine months of 2016, versus $9.6 million in the comparable 2015 period.
- Investing activities provided $5.0 million, primarily reflecting maturities of available-for-sale securities.
- Financing activities provided $107.2 million, including $84.5 million of net IPO proceeds and $22.5 million from the Series C preferred-stock financing.
- Stock-based compensation was $0.6 million for the first nine months of 2016, versus $0.1 million in the prior-year period.
Material Changes Versus the Prior Comparable Period
- First-nine-month research and development expense increased 121%, primarily due to PTG-100 clinical development, contract manufacturing, preclinical activities, higher headcount and consultant costs.
- Third-quarter research and development expense increased 76%, driven by consultants, PTG-100 manufacturing and increased employee-related costs.
- General and administrative expense increased 104% for the first nine months and 83% for the quarter, reflecting higher professional-service fees, headcount and public-company costs.
- Net loss increased 177% for the first nine months, partly because 2016 included a $4.7 million loss from remeasurement of preferred-stock tranche and warrant liabilities, compared with a $0.4 million gain in 2015.
- The August IPO issued 7.5 million shares at $12.00 per share; an additional 252,972 shares were issued in September after the underwriters exercised their option. Aggregate net cash proceeds were $83.6 million.
- All outstanding redeemable convertible preferred stock converted into 8.6 million common shares at the IPO closing, eliminating the preferred-stock balance and related liabilities.
- The company effected a one-for-14.5 reverse stock split on August 1, 2016; historical share and per-share data were retroactively adjusted.
Guidance, Outlook, Risks and Unusual Items
- Management believed existing cash, cash equivalents and available-for-sale securities would fund anticipated operating and capital requirements for at least 18 months from September 30, 2016.
- The company expects research and development spending to increase as PTG-100 advances, PTG-200 and PTG-300 progress through IND-enabling work, and additional programs advance.
- Management expects to require substantial additional capital to complete clinical development and potentially commercialize its candidates. Additional financing may dilute shareholders or require unfavorable debt, licensing or collaboration terms.
- Management stated that existing capital would not be sufficient to initiate pivotal clinical trials.
- The Australian research and development tax incentive generated a $1.9 million receivable at September 30, 2016. In October 2016, the company received approximately $2.2 million, including interest; $1.5 million related to overseas findings remained subject to potential clawback.
- The company owed a former collaboration partner up to $128.5 million in potential development, regulatory and sales milestones for PTG-300, plus a low-single-digit royalty on worldwide net sales if successfully commercialized.
- Disclosure controls and procedures were deemed ineffective because of a material weakness in internal control over financial reporting involving complex equity transactions and review and approval of manual journal entries. Remediation was in its initial phase.
- Key risks include clinical-trial failure or delay, regulatory non-approval, manufacturing and CRO dependence, intellectual-property challenges, competition, need for additional financing, foreign-currency exposure and inability to achieve product revenue or profitability.
- No material legal proceedings, defaults, repurchases or off-balance-sheet arrangements were reported.
Important Facts for Investors to Verify
- Whether the planned PTG-100 Phase 2b trial began on schedule and the resulting enrollment, safety and efficacy data.
- The pace and cost of PTG-200 and PTG-300 IND-enabling programs and any changes to development timelines.
- Actual cash-burn trends relative to the company’s stated 18-month liquidity expectation and the timing of future financing.
- Status of the material-weakness remediation and whether additional control deficiencies are identified.
- Potential obligations under the PTG-300 license, including milestone payments and royalties.
- Potential dilution from outstanding options, future equity offerings and shares becoming eligible for sale after lock-up expiration.
- Whether the Australian tax-incentive amounts subject to clawback are ultimately retained.